AstraZeneca gets FDA advisory panel nod for gout drug lesinurad
AstraZeneca Plc said a U.S. Food and Drug Administration advisory panel recommended approval of Lesinurad, a gout drug gained with the acquisition of Ardea Biosciences Inc. three years ago. The FDA’s Arthritis Advisory Committee voted 10 to 4 to clear the treatment in combination with traditional options such as Oxypurinol, Zyloprim or Uloric, the London-based drugmaker said in a statement.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063